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Background: Cancer may cause financial difficulties, but its impact in countries with public health systems is unknown.
We evaluated the association of financial difficulties with clinical outcomes of cancer patients enrolled in academic clinical
trials performed within the Italian public health system.
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Patients and methods: Data were pooled from 16 prospective multicentre trials in lung, breast or ovarian cancer,
using the EORTC quality of life (QOL) C30 questionnaire. Question 28 scores financial difficulties related to disease or
treatment in four categories from ‘not at all’ to ‘very much’. We defined financial burden (FB) as any financial difficulty
reported at baseline questionnaire, and financial toxicity (FT) as score worsening in a subsequent questionnaire. We
investigated (i) the association of FB with clinical outcomes (survival, global QOL response [questions 29/30] and severe
toxicity), and (ii) the association of FT with survival. Multivariable analyses were performed using logistic regression
models or the Cox model adjusting for trial, gender, age, region and period of enrolment, baseline global QOL and, where
appropriate, FB and global QOL response. Results are reported as odds ratio (OR) or hazard ratio (HR) with 95%
confidence intervals (CI).
Results: At baseline 26% of the 3670 study patients reported FB, significantly correlated with worse baseline global
QOL. FB was not associated with risks of death (HR 0.94, 95% CI 0.85–1.04, P ¼ 0.23) and severe toxicity (OR 0.90,
95% CI 0.76–1.06, P ¼ 0.19) but was predictive of a higher chance of worse global QOL response (OR 1.35, 95% CI
1.08–1.70, P ¼ 0.009). During treatment, 2735 (74.5%) patients filled in subsequent questionnaires and 616 (22.5%)
developed FT that was significantly associated with an increased risk of death (HR 1.20, 95% CI 1.05–1.37, P ¼ 0.007).
Several sensitivity analyses confirmed these findings.
Conclusion: Even in a public health system, financial difficulties are associated with relevant cancer patients outcomes
like QOL and survival.
Clinical Trials number: Any registered clinical trial number should be indicated after the abstract.
Key words: financial toxicity, public health system, quality of life, overall survival
introduction
Financial problems are matter of attention in oncology, primar-
ily due to the increasing cost of new drugs, unaffordable by
patients in health systems where co-payment is required [1].
However, financial difficulties might occur even in countries
where co-payment is not required (e.g. the Macmillan’s research
report ‘Revealing the costs behind the illness’ at http://www.
macmillan.org.uk, accessed 30 August 2016). In Italy, a NHS-
based (National Health Service) public health care system exists,
and most of the clinical pathway of cancer patients is cost-free,
including inpatient and outpatient services and drugs.
There are two levels of financial difficulties, the society level
and the patient level. The first is encumbered by the rising cost of
new drugs, that is a problem worldwide for both public payers
and patients, when co-payment is required [2]. Cancer patients
in the United States have higher likelihood to file for bankruptcy
than the general population [3]. In turn, financial difficulties
have been associated with lower patient satisfaction [4], worse
compliance [5], worse quality of life (QOL) [6–8], and worse sur-
vival [9].
Provocatively, it has been suggested that financial toxicity
might be graded similarly to traditional side effects, to help
researchers understand the economic impact of new drugs [10].
Also, it has been suggested that existing tools that measure finan-
cial problems should be investigated to understand whether
what they measure is associated with patients’ outcomes [11].
Question 28 (Q28) of the EORTC QLQ-C30 questionnaire for
QOL analysis asks ‘During the last week, has your physical condi-
tion or medical treatment caused you financial difficulties?’ [12].
We have frequently used the EORTC QLQ-C30 questionnaire in
clinical trials of treatment of solid tumours and planned to per-
form a pooled analysis of such trials, to explore whether (i) finan-
cial difficulties at baseline are associated with patients’ outcomes
(survival, QOL and toxicity), and (ii) the development of financial
difficulties during treatment is associated with overall survival.
methods
This study is an unplanned secondary analysis performed pool-
ing 16 prospective trials promoted by the National Cancer
Institute of Napoli (Italy) between 1996 and 2008 (supplemen-
tary Table S1. available at Annals of Oncology online). All trials
were approved by the Ethics Committees at participating
Institutions; their results have already been published (see refer-
ences in the online supplementary material, available at Annals
of Oncology online). Out of 162 participating centres, 160 were
public institutions, either general or university hospitals or can-
cer centres; two private centres were under contract with the
public system and, similarly, did not require any co-payment
from patients.
All patients enrolled in the pooled trials were eligible.
Exclusion criteria were (i) having been enrolled outside Italy and
(ii) missing response to Q28 at the baseline EORTC QLQ C30
questionnaire.
The EORTC QLQ-C30 questionnaire was administered with
varying schedules across trials, according to chemotherapy
cycles, from baseline to the end of cycle 6 (supplementary Table
S2, available at Annals of Oncology online); questionnaires com-
pleted on day 8 of cycle 1 (in 5 lung cancer trials) were not taken
into account in the present analysis. Response codes to Q28
range from 1 to 4, corresponding to ‘not at all’, ‘a little’, ‘quite a
bit’ and ‘very much’. For this study, the presence of financial dif-
ficulties at the baseline questionnaire and the worsening (or the
appearance) of financial difficulties in subsequent questionnaires
were coded in different ways. Namely, we called the former
‘Financial burden’ (FB) and the latter ‘Financial toxicity’ (FT).
Obviously, FT could be measured only among patients who ful-
filled at least one questionnaire after the baseline. FB and FT
were primarily analysed as binary variables (any grade versus not
at all), but three categories were also considered in sensitivity
analyses. Responses to questions 29 and 30 range from 1 (the
worst score) to 7 (the best score). They were combined and
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linearly transformed into the global health status/QOL scale
ranging from 0 to 100, hereby defined global QOL [13].
Variability of baseline global QOL according to categories of FB
at baseline was tested with the Kruskal–Wallis non parametric
ANOVA.
Geographic origin referred to the centres where the patients
were enrolled, because birth place and place of residency were
not recorded. Patients were clustered according to the enrolment
date into three time-windows: 1996–2001, 2002–2006, 2007–
2012.
Three outcome variables were evaluated: clinical toxicity,
QOL and survival.
Clinical toxicity was measured across the trials with different
subsequent editions of internationally accepted criteria: WHO,
NCI-CTC version 2, and CTCAE versions 2 and 3. Such variabil-
ity, however, does not affect intra-trial consistency and should
not affect the whole analysis. We calculated the worst grade
experienced by each patient over treatment in all toxicity items,
grades ranged from 0 (no toxicity) to 5 (toxicity-related death);
severe toxicity was defined as grade 3. The prognostic role of
FB for severe toxicity was reported as odds ratio (OR) with 95%
confidence interval (CI) and tested with a logistic model adjusted
for gender, age, region, period of enrolment, baseline global QOL
and trial.
Global QOL worsening was defined as a decrease of at least 10
points at any time point from baseline without any improvement
10 points at any time point over baseline [14]. The prognostic
role of FB on global QOL worsening was reported as OR with
95% CI and tested with a logistic model adjusted for gender, age,
region, period of enrolment, baseline global QOL and trial.
Survival was calculated as the number of months between ran-
domization and the date of death or of last information on vital
status. The prognostic role of FB on survival was reported as haz-
ard ratio (HR) of death with 95% CI and tested with a Cox pro-
portional hazard model stratified by trial and adjusted for
gender, age, region, period of enrolment and baseline global
QOL. To evaluate the role of FT on overall survival a Cox pro-
portional hazard model was used, stratified by trial and adjusted
by gender, age, region, period of enrolment, baseline FB, baseline
global QOL and global QOL response. To remove the bias due to
the time-dependent nature of financial toxicity, a landmark sur-
vival analysis was used with a landmark time of 4.5 months (i.e.
the maximum planned time to complete all the QLQ-C30 ques-
tionnaires); therefore, patients who died or had the last informa-
tion on vital status before 4.5 months from randomization were
excluded.
Because of possible heterogeneity among trials, sensitivity
analyses were performed excluding one single trial at a time, one
disease (lung or breast or ovary) at a time, and one setting (adju-
vant, metastatic) at a time. Further sensitivity analyses were per-
formed for the impact of FT on survival, varying the landmark
threshold from 4.5 months up to 24months.
results
Overall, 4722 patients had been enrolled in 16 trials; 252 patient
enrolled outside Italy were excluded and a further 800 were
excluded due to missing response to baseline Q28. Therefore,
3670 patients were included in the analysis.
Distribution of baseline characteristics, according to response
to baseline Q28 is reported in Table 1. Overall, 956 patients
(26.0%) reported at least some grade of FB. A lower percentage
of FB was found in Northern Italy, male gender, elderly and ear-
lier recruitment date.
Baseline global QOL significantly (P< 0.0001) decreased with
greater financial burden (supplementary Figure S1, available at
Annals of Oncology online).
Results of the models evaluating the prognostic role of FB on
clinical outcomes are reported in Table 2. Out of 3670 patients,
2473 (67.4%) died. FB was not significantly associated with the
risk of death, with a HR of 0.94 (95% CI 0.85–1.04, P¼ 0.23).
Global QOL response was calculated in 2703 (73.7%) patients;
of these, 917 (33.9%) worsened QOL without any previous
improvement. FB was significantly associated with worsening
global QOL (OR 1.35, 95% CI 1.08–1.70, P¼ 0.009). Clinical
toxicity data were available for 3573 (97.4%) patients; of these,
1586 (44.4%) had severe clinical toxicity. There was no associa-
tion between FB and occurrence of severe clinical toxicity (OR
0.90 95% CI 0.76–1.06, P ¼ 0.19). Similar results were found
when three categories were considered for FB (supplementary
Table S3, available at Annals of Oncology online). Sensitivity
analyses, performed removing trials, or disease or stage of dis-
ease, one at time, substantially confirmed all the previous find-
ings (supplementary Figures S2–S4, available at Annals of
Oncology online).
Overall, 2735 (74.5%) patients answered Q28 of the QLQ-C30
questionnaire at least once after the baseline. Of these, 58 (2.0%)
had reported the worst score (very much) at the baseline ques-
tionnaire and by definition could not develop financial toxicity
during the treatment; 616 (22.5%) developed financial toxicity
while on treatment (Table 3), ranging from 8.3% to 40.7% across
the different clinical trials (supplementary Table S4, available at
Annals of Oncology online).
Financial toxicity was associated with a statistically significant
higher risk of death (HR 1.20, 95% CI 1.05–1.37, P¼ 0.007),
when the landmark time of 4.5 months was used. Similar results
were found when three categories were considered for FT (sup-
plementary Table S3, available at Annals of Oncology online).
Results did not vary in sensitivity analyses when landmark
threshold was increased (Figure 1) and trials, or disease or stage
of disease were removed one at a time (supplementary Figure S5,
available atAnnals of Oncology online).
discussion
We found that in a large series of Italian cancer patients enrolled
in clinical trials, about one-quarter had some FB at baseline, and
a further 22% developed FT while on treatment. Baseline FB was
associated with a clinically relevant worsening of QOL during
the treatment, and FT that developed during treatment was sig-
nificantly associated with an increased risk of death. Such find-
ings, particularly the latter, were unexpected in the public Italian
health system setting.
Due to the study design, it cannot be established to what extent
baseline FB may be confounded by socio-economic condition.
Further, FT cannot be disentangled from disease progression,
that is whether FT directly causes mortality or rather it is a conse-
quence of cancer progression, that ultimately causes death.
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However, we can exclude that financial problems led to differen-
tial access to anticancer drugs, because in Italy no co-payment
for anticancer drugs is required. Therefore, our data extend the
matter of financial difficulties beyond the cost of antineoplastic
drugs. We may also speculate that it is unlikely that the effect of
FT on survival be due to the increasing expenses close to the end
of life [15], because results did not change with increasing the
landmark time for survival analysis. Therefore, our data show
that financial difficulties are a problem worthy of investigation
even in public health frameworks.
Table 1. Distribution of patients according to baseline characteristics and baseline ﬁnancial burden
Total
N¼ 3670
During the last week, has your physical condition or medical treatment caused you financial
difficulties?
P
Not at all
N¼ 2714
A little
N¼ 669
Quite a bit
N¼ 205
Very much
N¼ 82
n n (%) n (%) n (%) n (%)
Trial—type of cancer <0.001
1. BREAST10—breast 126 83 (65.9%) 27 (21.4%) 11 (8.7%) 5 (4.0%)
2. CAPPA2—NSCLC 37 23 (62.2%) 11 (29.7%) – 3 (8.1%)
3. DISTAL—NSCLC 192 124 (64.6%) 47 (24.5%) 15 (7.8%) 6 (3.1%)
4. DISTAL2—NSCLC 73 39 (53.4%) 18 (24.7%) 10 (13.7%) 6 (8.2%)
5. EDD—breast 16 6 (37.5%) 4 (25.0%) 3 (18.8%) 3 (18.8%)
6. ELDA—breast 251 158 (62.9%) 76 (30.3%) 12 (4.8%) 5 (2.0%)
7. ELVIS—NSCLC 149 119 (79.9%) 24 (16.1%) 6 (4.0%) –
8. GECO—NSCLC 358 259 (72.3%) 65 (18.2%) 21 (5.9%) 13 (3.6%)
9. GEMVIN2—NSCLC 129 94 (72.9%) 23 (17.8%) 10 (7.8%) 2 (1.6%)
10. GEMVIN3—NSCLC 342 252 (73.7%) 68 (19.9%) 16 (4.7%) 6 (1.8%)
11. G-STEP—SCLC 62 58 (93.5%) 4 (6.5%) – –
12. MILES—NSCLC 594 506 (85.2%) 66 (11.1%) 17 (2.9%) 5 (0.8%)
13. MILES2—NSCLC 193 169 (87.6%) 19 (9.8%) 4 (2.1%) 1 (0.5%)
14. MITO2—ovary 617 402 (65.2%) 147 (23.8%) 54 (8.8%) 14 (2.3%)
15. TAXw—breast 38 32 (84.2%) 4 (10.5%) 1 (2.6%) 1 (2.6%)
16. TORCH—NSCLC 493 390 (79.1%) 66 (13.4%) 25 (5.1%) 12 (2.4%)
Age <0.001
65 1654 1106 (66.9%) 354 (21.4%) 136 (8.2%) 58 (3.5%)
>65 2016 1608 (79.8%) 315 (15.6%) 69 (3.4%) 24 (1.2%)
Gender <0.001
Males 2120 1654 (78.0%) 327 (15.4%) 97 (4.6%) 42 (2.0%)
Females 1550 1060 (68.4%) 342 (22.1%) 108 (7.0%) 40 (2.6%)
Region <0.001
North 956 804 (84.1%) 113 (11.8%) 31 (3.2%) 8 (0.8%)
Centre 509 343 (67.4%) 109 (21.4%) 41 (8.1%) 16 (3.1%)
South/islands 2205 1567 (71.1%) 447 (20.3%) 133 (6.0%) 58 (2.6%)
Period of enrolment <0.001
1996–2001 1353 1071 (79.2%) 208 (15.4%) 57 (4.2%) 17 (1.3%)
2002–2006 1456 1028 (70.6%) 293 (20.1%) 97 (6.7%) 38 (2.6%)
2007–2012 861 615 (71.4%) 168 (19.5%) 51 (5.9%) 27 (3.1%)
Table 2. Association of ﬁnancial burden and ﬁnancial toxicity with clinical outcomes
Variable and outcome Model n Events Measure Value 95% CI P
Baseline ﬁnancial burden (any grade versus not at all)
Overall survival Cox modela 3655 2462 HR of death 0.94 0.85–1.04 0.23
Global QoL Logistic regressiona 2703 917 OR of worsening 1.35 1.08–1.70 0.009
Clinical toxicity Logistic regressiona 3558 1579 OR of grade  3 0.90 0.76–1.06 0.19
Financial toxicity (1-point worsening versus no-worsening)
Overall survival (4.5 months landmark) Cox modelb 2263 1382 HR of death 1.20 1.05–1.37 0.007
HR, hazard ratio; OR, odds ratio.
aAdjusted by gender, age, period, region, baseline global QOL (15 cases with data missing) and trial.
bAdjusted by gender, age, period, region, baseline response to Q28, baseline global QOL (15 cases with data missing), global QOL response and trial.
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Our study has some weaknesses. First, the population was
selected for participation in a clinical trial, and may not be repre-
sentative of the general cancer population in Italy and at risk of
underrepresentation of patients with poor socio-economic status
[16]. Second, as the present analysis was not planned when the
clinical trials were performed, we did not collect information on
demographics, socio- economic status and education level and
cannot adjust for these possible confounders. Also, the location
of the recruitment centre was used as a proxy for the place of ori-
gin of the patients and confusion could arise from the fact that
some patients from Southern Italy migrate to Northern regions
for cancer treatment (see the 2016 FAVO report at http://www.
favo.it/ottavo-rapporto.html, accessed 30 August 2016). Third,
we cannot speculate on factors predictive of financial burden or
toxicity, because the patient population was not consecutive but
selected according to availability of clinical trials and inclusion/
exclusion criteria. Therefore, caution is required in interpreting
the rate of patients with FB or FT as a measure of prevalence,
because they might be biased. Finally, Q28 of the EORTC QLQ-
C30 is a single-item question that does not allow distinction
between financial difficulties generated by the cancer physical
condition or the medical treatment itself.
However we believe that our study also has a number of
strengths. First, it includes a very large series of patients, to our
knowledge the largest ever based on prospective data collection
and not originating from public registries, thus preventing typi-
cal selection bias of observational studies or cross-sectional sur-
veys. Second, due to the trials’ long term follow-up, we were able
to prospectively measure the association of FB and FT with rele-
vant clinical outcomes. Accordingly, we were able to distinguish
between the prevalent FB and the incident FT, while these meas-
ures are usually confused in retrospective or cross-sectional stud-
ies. Third, the pragmatic approach of all the clinical trials pooled
for this analysis, makes our findings reasonably generalizable to
clinical practice, although validation is warranted. Fourth, sensi-
tivity analyses confirm that our findings are robust and not sub-
stantially affected by any possible outlier trial. Further, all
analyses were adjusted for global QOL (EORTC-C30 questions
Table 3.. Distribution of patients according to responses given to baseline question 28 and the worst response given to question 28 in the subsequent
questionnaires
Response to question 28 at baseline Total Worst response to question 28 at subsequent questionnaires
Not at all A little Quite a bit Very much
n n (%) n (%) n (%) n (%)
Not at all 2015 1540 (76.4%) 358 (17.8%) 91 (4.5%) 26 (1.3%)
A little 508 115 (22.6%) 282 (55.5%) 91 (17.9%) 20 (3.9%)
Quite a bit 154 12 (7.8%) 41 (26.6%) 71 (46.1%) 30 (19.5%)
Very much 58 2 (3.4%) 14 (24.1%) 15 (25.9%) 27 (46.6%)
Bold numbers represent cases who are labelled as any ﬁnancial toxicity. Grey cell refer to moderate and severe worsening.
Landmark time
4.5 months 2263
1832
1671
1518
1376
992
767
2031
1382
1008
877
750
632
352
204
1181
1.20 (1.05–1.37) 0.007
0.02
0.03
0.02
0.04
0.06
0.04
0.09
0.9 1.0 1.1 1.2 1.3
HR of death
1.4 1.5 1.6 1.7 1.8 1.9 2.0
(1.03–1.38)
(1.02–1.39)
(1.03–1.44)
(1.01–1.47)
(0.99–1.49)
(1.02–1.73)
(0.96–1.92)
1.19
1.22
1.22
1.22
1.32
1.36
1.196 months
7.5 months
9 months
10.5 months
12 months
18 months
24 months
N Events HR (95% Cl) P
Figure 1. Association of ﬁnancial toxicity with overall survival by variable landmark times (adjusted by gender, age, period, region, trial, baseline global
QOL, global QOL response and baseline response to question 28). HR, hazard ratio. The size of the square is proportional to sample size.
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29–30), either as baseline QOL or QOL response during the trial,
that is recognized as an important prognostic factor in many set-
tings (e.g. lung cancer [17]) and roughly stands as a proxy for
many other potential confounding factors, both at baseline and
during treatment. Fifth, as far as we know, this is the first report
suggesting that financial problems might play a role in cancer
patients’ outcomes outside the US and in a public health system.
However, we acknowledge that, even in a public third-payer
framework where most services are cost free at the point of deliv-
ery, patients may pay for some services, like drugs for minor side
effects which are not covered by the public payer, outpatient and
inpatient services privately accessed, home health services. The
latter might occur because of long waiting lists, or because
patients want to be treated by or have a second opinion by a
health care professional who is not available through the public
system. In such a context, patients might be more sensitive to the
impact of financial constraints outside the health care system
(e.g. working days lost by the patient or their relatives’ travel and
sojourn expenses if treated in a distant town, as also suggested by
the Macmillan’s research report ‘Revealing the costs behind the
illness’ at http://www.macmillan.org.uk, accessed 30 August
2016).
More appropriate and context-driven measurement tools are
needed. The COST score, a patient-reported-outcome instru-
ment, has been recently proposed as a tool for measuring finan-
cial distress in US [18]. It is a questionnaire composed of 11
items, derived from an initial list of 147. This instrument has
been applied to a cross-sectional pilot study including 100
insured multiple myeloma patients after at least 3 months of
medical treatment [19]. However, it is not clear whether this
questionnaire may work in different health systems.
For the future, a deeper understanding of the factors causing
financial difficulty is required with the use of specific multidi-
mensional instruments, tailored to the different socio-cultural
contexts. With knowledge of causes and risk of financial diffi-
culty, interventional strategies can be planned from optimization
of health services to intensification of social support or steward-
ship activities in favour of cancer patients.
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